This trial is studying the airway immune response to inhaled allergens in people with and without asthma to see what promotes the disease.
5 Primary · 3 Secondary · Reporting Duration: 18 months
Experimental Treatment
12 Total Participants · 1 Treatment Group
Primary Treatment: Segmental allergen challenge · No Placebo Group · Phase 1
Age 18 - 50 · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: